{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"353.0","upperLimit":"666.0","value":"558.0"},{"groupId":"OG001","lowerLimit":"414.0","upperLimit":"1093.0","value":"536.0"}]}]}],"denomUnitsSelected":"events","denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"22"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"}],"units":"events"}],"description":"Time to disease progression is defined as the time from baseline to disease progression or death.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants received ofatumumab intravenously (IV) in Cycle 1 (defined as a treatment period of up to 4 weeks \\[Weeks (Wk.) 1 through 4\\]) (300 milligrams \\[mg\\] at Week 1 and 1000 mg at Weeks 2 through 4) and were followed up for 11 weeks (Weeks 5-16). After Week 16, during the Redosing Cycle (RC), participants who had Minor Response or stable disease after Cycle 1 and had not received another Waldenstrom's Macroglobulinemia (WM) therapy received 300 mg IV ofatumumab at Week 1 and 2000 mg IV ofatumumab at Weeks 2 through 5. Participants who achieved a response in either Cycle 1 or the RC and subsequently progressed before 36 months entered Cycle 2 of treatment and received IV ofatumumab 300 mg at Week 1 and IV ofatumumab 2000 mg during Weeks 2 through 5.","id":"OG000","title":"300 mg Ofatumumab, Wk. 1; 1000/2000 mg Ofatumumab, Wk. 2-4/2-5"},{"description":"Participants received ofatumumab IV at 300 mg at Week 1 and 2000 mg at Weeks 2 through 5 in Cycle 1 (defined as a treatment period of up to 5 weeks \\[Weeks 1 through 5\\]) and were followed up for 10 weeks (Weeks 6-16). After Week 16, during the RC, participants who had Minor Response or stable disease after Cycle 1 and had not received another WM therapy received 300 mg IV ofatumumab at Week 1 and 2000 mg IV ofatumumab at Weeks 2 through 5. Participants who achieved a response and subsequently progressed before 36 months entered Cycle 2 of treatment and received 300 mg at Week 1 and 2000 mg during Weeks 2 through 5.","id":"OG001","title":"300 mg Ofatumumab, Wk. 1; 2000 mg Ofatumumab, Wk. 2-5"}],"paramType":"MEDIAN","populationDescription":"ITT Population. Participants who experienced disease progression or death were counted as events, and other participants were censored at the time of the last adequate assessment in the study.","reportingStatus":"POSTED","timeFrame":"From baseline up to approximately 5 years","title":"Progression-free Survival","type":"SECONDARY","typeUnitsAnalyzed":"events","unitOfMeasure":"days"}